Healthtech spotlight: Jack Fertility

Founders of Jack Fertility wearing black and white Jack Fertility branded clothing

Jack Fertility has recently launched its £500K fundraising campaign to bring the world’s first home-to-lab sperm test kit to market. We had a chat with Co-founders, Lily Elsner and Nick Shipley, to hear their story… Jack Fertility at a glance: Start date: 2022 Market sector: Healthtech Location: Oxford Number of employees: 3 Amount of funding raised: £125k + government…

Read More

Cell technology spinout Impulsonics closes £450k funding

Impulsonics founders at NEC competition

Impulsonics has closed its first funding round to advance the development of its unique biotech automation platform and begin customer trials. Impulsonics is an award-winning cell technology spinout from the University of Bristol’s Ultrasonics and Non-Destructive Testing Research Group, building on over a decade of deep research and leveraging world-leading expertise in acoustics. The company…

Read More

Biotech startup Impulsonics awarded £300,000 Innovate UK grant

Impulsonics founders at NEC competition

Bristol-based startup, Impulsonics has been awarded the prestigious ICURe spinout support grant of £300,000 to enable the development of its unique technology platform for biotech automation. The grant will enable the company to develop its flexible acoustic platform for key applications in the process of growing cells in order to streamline cell culture automation. This…

Read More

Rosa Biotech secures £415,000 to accelerate early disease screening

Three Rosa Biotech scientists in lab looking at samples

Bio-sensing pioneer Rosa Biotech has secured £415,000 from angel investors and announced plans to accelerate development of its bio-sensing technology, designed to enable cost effective, early-stage screening of a range of life-threatening diseases. The University of Bristol healthtech spinout joined SETsquared Bristol in February 2023. It is initially targeting the early identification of non-alcoholic fatty…

Read More

Ferryx: Innovative biotech solutions to common gut problems

Ferryx - Ferrocalm package design, hand holding package with turquoise background

We had a chat with Dr Jenny Bailey, Co-founder and CEO of Ferryx, to hear her story. The University of Bristol spin-out has recently raised £300k seed capital and been awarded an Innovate Fast Start grant for further development of its innovative solution to common gut problems. Ferryx key facts: Start date:  September 2019 Market sector: Healthtech…

Read More

Healthtech products – from innovation to implementation

There is a vibrant healthtech* cluster in the South West region, with over 90 healthtech startups alone in Bristol. This sector has huge potential for Bristol, but it also has significant market challenges, from how to navigate the NHS to the rapidly evolving international digital regulatory landscape. In this article we share advice for healthtech…

Read More

Biotech spin-out Ferryx secures seed funding

Bristol-based biotech startup, Ferryx, has raised £300k seed capital from Deepbridge Capital for further development of its innovative solution to common gut problems. Ferryx is a University of Bristol spin-out company that joined SETsquared Bristol in 2020 and has since won ‘Best Elevator Pitch’ at our Tech-Xpo 2021 Showcase. The company aims to tackle the…

Read More

Biomaterials startup Zentraxa announce seed investment

Our member company and University of Bristol spin-out, Zentraxa, has raised capital investment from Future Planet Capital, BPEC and Science Angel Syndicate to develop their innovative Zentide platform for engineering bespoke biomaterials. With generous support of their recently awarded Innovate UK grant, Zentraxa is rapidly moving towards contracted commercial concept development in both medical adhesives…

Read More

GenomeKey raise Innovate UK funding to drive life-saving next-gen sepsis diagnostic

Our member GenomeKey, has secured an Innovate UK Biomedical Catalyst research award of £950,000 towards faster diagnosis and treatment of sepsis, one of the world’s most deadly diseases. The funding will enable the Bristol-based research and development company to provide rapid bacterial species identification and antimicrobial profiling in the hospital, which will save lives, save money,…

Read More